<DOC>
	<DOCNO>NCT01105429</DOCNO>
	<brief_summary>BMS-820132 investigational new drug develop BMS treat Type 2 diabetes . The purpose study test safety/tolerability ( potential side effect ) single dose investigational new drug , well amount study drug blood , subject type 2 diabetes .</brief_summary>
	<brief_title>Single Ascending Dose Study BMS-820132 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males female childbearing potential ( willing use acceptable method contraception ) , females nonchildbearing potential ( i.e. , postmenopausal surgically sterile ) Diagnosis type 2 diabetes treat metformin monotherapy stable regimen least 2 month Body Mass Index ( BMI ) 18 40 kg/m2 Fasting glucose range 100250 mg/dL Hemoglobin A1c ( HbA1c ) range 6.5 % 9.5 % Clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Any significant acute chronic medical illness stable well control hypertension , microalbuminuria , dyslipidemia , depression Past history diabetic ketoacidosis and/or Cpeptide &lt; 1.0 ng/mL , hyperosmolar nonketotic syndrome , lactic acidosis , recurrent hypoglycemia Any major surgery within 4 week study drug administration Any gastrointestinal surgery could impact upon absorption study drug Smoking 10 cigarette per day Recent drug alcohol abuse Women pregnant breastfeed Positive urine screen drug abuse Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV1 , 2 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>